Merck

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that clesrovimab injection, the world’s first single...

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has...

Company Drug PIC

EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk

Fineline Cube Aug 26, 2026

Gilead Sciences (NASDAQ: GILD) announced that the European Commission (EC) has granted marketing authorisation for...

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Fineline Cube Aug 25, 2026

The U.S. Court of Appeals for the Third Circuit ruled against Merck & Co., Inc....

Company Deals PIC

MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development

Fineline Cube Aug 12, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that it has signed a collaboration agreement...

Others PIC

Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children

Fineline Cube Aug 7, 2026

Merck & Co., Inc. (MSD, NYSE: MRK) announced that the U.S. Food and Drug Administration...

Company Drug

Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference

Fineline Cube Jul 22, 2026

Gilead Sciences, Inc. (NASDAQ: GILD) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that...

Company Drug

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

Fineline Cube Jul 17, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...

Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Fineline Cube Jul 16, 2026

Merck KGaA (ETR: MRK) announced on July 8, 2026, that the US Food and Drug...

Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Fineline Cube Jul 15, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced that its Phase III clinical study evaluating sacituzumab...

Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic agreement with the ADAP Crisis...

Company Drug

MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC

Fineline Cube Jun 9, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today...

Company Drug

MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Fineline Cube Jun 8, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced the official commercial launch of Winrevair (sotatercept)...

Company Drug

Merck’s Calderasib-Pembrolizumab Combination Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutant NSCLC

Fineline Cube Jun 1, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...

Company Drug

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Fineline Cube May 22, 2026

Merck KGaA (ETR: MRK) announced the initiation of the Phase III PROCEADE-CRC-03 study, evaluating the...

Company Drug

Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU

Fineline Cube May 22, 2026

Astellas Pharma Inc. (TYO: 4503) announced that the Committee for Medicinal Products for Human Use...

Company Drug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube May 11, 2026

Shanghai Henlius Biotech Inc. (HKG: 2696) announced it has received Investigational New Drug (IND) clearance...

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Fineline Cube May 9, 2026

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has submitted a new indication approval...

Company Drug

Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Fineline Cube Apr 15, 2026

Shanghai Henlius Biotech, Inc. (HKG: 2696), a leading Chinese biopharmaceutical company, announced it has received...

Company Drug

Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC

Fineline Cube Apr 14, 2026

Daiichi Sankyo (TYO: 4568) and Merck & Co., Inc. (MSD; NYSE: MRK) announced that the...

Merck

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

EC Approves Gilead’s Trodelvy Plus Keytruda for First‑Line PD‑L1‑Positive Metastatic TNBC – 35% Reduction in Progression Risk

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development

Merck Secures FDA Acceptance for Enflonsia sBLA to Expand RSV Prevention Through Second Season in High-Risk Children

Gilead and Merck to Present Phase 3 ISLEND Trial Data for Once-Weekly Oral HIV Regimen at AIDS 2026 Conference

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Kelun-Biotech’s Sacituzumab Tirumotecan Achieves World’s First ADC-Immunotherapy Phase III Success in PD-L1-Negative NSCLC

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC

MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Merck’s Calderasib-Pembrolizumab Combination Receives FDA Breakthrough Therapy Designation for First-Line KRAS G12C-Mutant NSCLC

Merck KGaA Launches Phase III PROCEADE-CRC-03 Trial for First-in-Class CEACAM5 ADC Precemtabart Tocentecan in Metastatic Colorectal Cancer

Astellas and MSD’s PADCEV-Keytruda Combination Receives Positive CHMP Opinion for Muscle-Invasive Bladder Cancer in EU

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Daiichi Sankyo-Merck Ifinatamab Deruxtecan Granted FDA Priority Review for Extensive-Stage SCLC

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories